{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:22:58Z","timestamp":1789708978532,"version":"4.0.1"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi230165-4\"><jats:title>Importance<\/jats:title><jats:p>Outcomes of localized malignant pleural mesothelioma (MPM) remain poor despite multimodality therapy. It is unclear what role disparities have in the overall survival (OS) of patients with operable MPM.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230165-5\"><jats:title>Objective<\/jats:title><jats:p>To examine survival disparities associated with social determinants of health (SDOHs) and treatment access in patients with malignant pleural mesothelioma.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230165-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>In this observational, retrospective cohort study, patients with MPM diagnosed between January 1, 2004, and December 31, 2017, were identified from the National Cancer Database with a maximum follow-up time of 13.6 years. The analysis was conducted from February 16, 2022, to July 29, 2022. Patients were included if they were diagnosed with potentially resectable clinical stage I to IIIA MPM, had epithelioid and biphasic histologic subtypes, and received chemotherapy. Patients were excluded if they could not receive curative surgery, were 75 years or older, or had metastasis, unknown stage, or tumor extension to the chest wall, mediastinal tissues, or organs.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230165-7\"><jats:title>Exposures<\/jats:title><jats:p>Chemotherapy alone vs chemotherapy with curative surgery in the form of pleurectomy and decortication or extrapleural pneumonectomy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230165-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end point was OS. Cox proportional hazards regression models were used to determine hazard ratios (HRs) for OS, including univariable and multivariable models controlling for potential confounders, including demographic, comorbidity, clinical, treatment, tumor, and hospital-related variables, as well as SDOHs.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230165-9\"><jats:title>Results<\/jats:title><jats:p>A total of 1389 patients with MPM were identified (median [IQR] age, 66 [61-70] years; 1024 [74%] male; 12 [1%] Asian, 49 [3%] Black, 74 [5%] Hispanic, 1233 [89%] White, and 21 [2%] of other race). The median OS was 1.7 years (95% CI, 1.6-1.8). Risk factors associated with worse OS included older age, male sex, Black race, low income, and low educational attainment. Factors associated with greater odds of survival included receipt of surgical therapy, recent year of treatment, increased distance to travel, and treatment at high-volume academic hospitals. The risk factors most strongly associated with poor OS included Black race (HR, 1.96; 95% CI, 1.43-2.69) and male sex (HR, 1.60; 95% CI, 1.38-1.86). Surgical treatment in addition to systemic chemotherapy (HR, 0.70; 95% CI, 0.61-0.81) was independently associated with improved OS, as were chemotherapy initiation (HR, 0.93; 95% CI, 0.87-0.99) and greater travel distance from the hospital (HR, 0.92; 95% CI, 0.86-0.98).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230165-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this retrospective cohort study of patients with operable MPM, there was significant variability in access to care by SDOHs. Addressing disparities in access to multimodality therapy can help ensure equity of care for patients with MPM.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.4261","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T15:02:13Z","timestamp":1679583733000},"page":"e234261","source":"Crossref","is-referenced-by-count":18,"title":["Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma"],"prefix":"10.1001","volume":"6","author":[{"given":"Ahmed","family":"Alnajar","sequence":"first","affiliation":[{"name":"Division of Cardiothoracic Surgery, Department of Surgery, University of Miami Leonard M. Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Kareff","sequence":"additional","affiliation":[{"name":"Jackson Memorial Hospital, University of Miami Leonard M. Miller School of Medicine, Miami, Florida"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami Leonard M. Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed S.","family":"Razi","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Memorial Healthcare System, Hollywood, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Sunil","family":"Rao","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Public Health Sciences, University of Miami Leonard M. Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"De Lima Lopes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao M.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic Surgery, Department of Surgery, University of Miami Leonard M. Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor","family":"Villamizar","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic Surgery, Department of Surgery, University of Miami Leonard M. Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelamari","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, University of Miami Leonard M. Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"issue":"6","key":"zoi230165r1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s10903-020-01038-x","article-title":"Racial disparities in treatment patterns and survival among surgically treated malignant pleural mesothelioma patients.","volume":"22","author":"Alpert","year":"2020","journal-title":"J Immigr Minor Health"},{"issue":"3","key":"zoi230165r2","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.athoracsur.2019.03.052","article-title":"Disparities in compliance with national guidelines for the treatment of malignant pleural mesothelioma.","volume":"108","author":"Espinoza-Mercado","year":"2019","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"zoi230165r3","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.21037\/jtd","article-title":"A narrative review of the health disparities associated with malignant pleural mesothelioma.","volume":"13","author":"Freudenberger","year":"2021","journal-title":"J Thorac Dis"},{"issue":"8","key":"zoi230165r4","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1089\/lap.2012.0095","article-title":"Disparities in access to video-assisted thoracic surgical lobectomy for treatment of early-stage lung cancer.","volume":"22","author":"Stitzenberg","year":"2012","journal-title":"J Laparoendosc Adv Surg Tech A"},{"issue":"3","key":"zoi230165r5","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.athoracsur.2020.03.048","article-title":"National utilization of surgery and outcomes for primary tracheal cancer in the United States.","volume":"110","author":"Benissan-Messan","year":"2020","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"zoi230165r6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Geographic access to cancer care in the U.S.","volume":"112","author":"Onega","year":"2008","journal-title":"Cancer"},{"issue":"9","key":"zoi230165r7","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/JCO.2013.52.3845","article-title":"Association between travel distance and metastatic disease at diagnosis among patients with colon cancer.","volume":"32","author":"Massarweh","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi230165r8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252381","article-title":"Greater travel distance to specialized facilities is associated with higher survival for patients with soft-tissue sarcoma: US nationwide patterns.","volume":"16","author":"Fujiwara","year":"2021","journal-title":"PLoS One"},{"issue":"9","key":"zoi230165r9","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1177\/0003134820943649","article-title":"Does distance to treatment affect mortality rate for surgical oncology patients?","volume":"86","author":"Garstka","year":"2020","journal-title":"Am Surg"},{"key":"zoi230165r10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.lungcan.2020.05.032","article-title":"Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: a Surveillance, Epidemiology, and End Results (SEER) study.","volume":"146","author":"Thompson","year":"2020","journal-title":"Lung Cancer"},{"issue":"13","key":"zoi230165r11","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1245\/s10434-021-10653-3","article-title":"Geographic disparities in oncologic treatment and outcomes: the urban-rural divide.","volume":"28","author":"Diaz","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"zoi230165r12","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/282145","article-title":"Frequency of surgery in black patients with malignant pleural mesothelioma.","volume":"2015","author":"Taioli","year":"2015","journal-title":"Dis Markers"},{"issue":"10","key":"zoi230165r13","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1097\/JTO.0b013e3181f1903e","article-title":"Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population.","volume":"5","author":"Flores","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"2","key":"zoi230165r14","first-page":"21","article-title":"The Hispanic paradox in non-small cell lung cancer.","volume":"15","author":"Kumar","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"28","key":"zoi230165r15","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1200\/JCO.2012.48.6217","article-title":"How do social factors explain outcomes in non-small-cell lung cancer among Hispanics in California? explaining the Hispanic paradox.","volume":"31","author":"Patel","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi230165r16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.","volume":"16","author":"Curran","year":"1998","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi230165r17","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1016\/j.cllc.2020.05.021","article-title":"Gender-based disparities in receipt of care and survival in malignant pleural mesothelioma.","volume":"21","author":"Barsky","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"zoi230165r18","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.athoracsur.2017.09.036","article-title":"National trends in the epidemiology of malignant pleural mesothelioma: a National Cancer Data Base study.","volume":"105","author":"Saddoughi","year":"2018","journal-title":"Ann Thorac Surg"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2802746\/alnajar_2023_oi_230165_1678906339.40292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T15:02:30Z","timestamp":1679583750000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2802746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.4261","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}